MARKET

NGNE

NGNE

Neurogene
NASDAQ
21.63
-0.67
-3.00%
Opening 10:11 03/13 EDT
OPEN
22.30
PREV CLOSE
22.30
HIGH
22.32
LOW
21.25
VOLUME
20.65K
TURNOVER
--
52 WEEK HIGH
37.27
52 WEEK LOW
6.88
MARKET CAP
335.04M
P/E (TTM)
-5.2547
1D
5D
1M
3M
1Y
5Y
1D
Neurogene management to join Stifel Virtual CNS Forum fireside chat
Reuters · 2d ago
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
Barchart · 2d ago
Weekly Report: what happened at NGNE last week (0302-0306)?
Weekly Report · 4d ago
Neurogene President and CFO Christine Mikail Cvijic Disposes of Common Shares
Reuters · 03/03 22:38
Neurogene Grants Inducement Stock Options to Four New Employees
Reuters · 03/03 21:01
NEUROGENE ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/03 21:01
Analysts Are Bullish on Top Healthcare Stocks: Mesoblast Limited (MEOBF), Neurogene (NGNE)
TipRanks · 03/02 16:20
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 03/02 13:07
More
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Webull offers Neurogene Inc stock information, including NASDAQ: NGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGNE stock methods without spending real money on the virtual paper trading platform.